Sunanta ChariyalertsakWichai PurisaPensri Saelee2011-02-222011-02-222011-02-112011-02-11Thai Cancer Journal; Vol.30 No.4 October-December 2010; 153-159http://imsear.searo.who.int/handle/123456789/132397A new class of glutathione S-transferase enzymes, named omega, (GSTO) has recently been identified and shown to be expressed in various human tissues. Though GSTO1 and GSTO2 polymorphisms have been reported and found to be associated with the risk of certain cancers, their correlation with cancer-patient outcomes has been demonstrated in a very small number of studies. The aim of this study was to evaluate the potential relationship between GSTO2 polymorphism and clinical outcome parameters and the disease-free survival of breast-cancer patients. DNA was extracted from the formalin-fixed, paraffin-embedded breast-cancer tissues of 83 patients; gene polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). No significant association was found between GSTO2 polymorphism and clinical outcome parameters or five-year disease-free patient survival. It was concluded that GSTO2 polymorphism does not influence the clinical outcome or survival of breast cancer patients. (Thai Cancer J 30;4:153-159)en-USNational Cancer Institute of Thailand, Bangkok, ThailandResearch Articles